Skip to main content
M

Mabpharm Limited — Investor Relations & Filings

Ticker · 2181 HKEX Manufacturing
Filings indexed 221 across all filing types
Latest filing 2022-04-21 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2181

About Mabpharm Limited

http://www.mabpharm.cn

Mabpharm Limited is a biopharmaceutical company focused on the research, development, production, and commercialization of monoclonal antibody (mAb) drugs and biosimilars. The core therapeutic areas include oncology (cancer) and autoimmune diseases. The company emphasizes bringing high-quality, affordable, and innovative biological drugs to the market by utilizing efficient R&D systems and low-cost manufacturing capabilities. Its robust pipeline features multiple candidates, including 9 monoclonal antibody drugs and 1 strong antibody drug.

Recent filings

Filing Released Lang Actions
2021 Annual Report
Regulatory Filings
2022-04-21 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022
Regulatory Filings
2022-04-06 English
VOLUNTARY ANNOUNCEMENT EXCLUSIVE PROMOTION SERVICE AGREEMENT WITH KEXING BIOPHARM REGARDING CMAB008 (INFLIXIMAB) IN MAINLAND CHINA
Regulatory Filings
2022-03-31 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021
Regulatory Filings
2022-03-25 English
PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION
Regulatory Filings
2022-03-25 English
DATE OF BOARD MEETING
Regulatory Filings
2022-03-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.